LEF1 (C18A7) Rabbit mAbProduct information
|100 µl (10 western blots)||-||Unavailable in your region|
Product Pathways - Development
LEF1 (C18A7) Rabbit mAb #2286
|2286S||100 µl (10 western blots)||---||In Stock||---|
|2286||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human, Mouse, Rat||Endogenous||25-58||Rabbit IgG|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Specificity / Sensitivity
LEF1 (C18A7) Rabbit mAb detects endogenous level of total LEF1 proteins, including the dominant negative forms due to the usage of alternative promoter.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val282 of human LEF1.
LEF1 and TCF are members of the high mobility group (HMG) DNA binding protein family of transcription factors that consists of the following: Lymphoid Enhancer Factor 1 (LEF1), T Cell Factor 1 (TCF1/TCF7), TCF3/TCF7L1, and TCF4/TCF7L2 (1). LEF1 and TCF1/TCF7 were originally identified as important factors regulating early lymphoid development (2) and act downstream in Wnt signaling. LEF1 and TCF bind to Wnt response elements to provide docking sites for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1 and TCF are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers including colon cancer (4,5).
LEF1 has several isoforms due to alternative splicing. LEF1 also has an alternative promoter that is preferentially active in lymphocytes. The isoforms generated by this alternative promoter have no amino-terminal β-catenin binding domain, therefore, they may function in a dominant negative manner (6-8).
- Waterman, M.L. (2004) Cancer Metastasis Rev 23, 41-52.
- Schilham, M.W. and Clevers, H. (1998) Semin Immunol 10, 127-32.
- Brantjes, H. et al. (2002) Biol Chem 383, 255-61.
- Reya, T. and Clevers, H. (2005) Nature 434, 843-50.
- Logan, C.Y. and Nusse, R. (2004) Annu Rev Cell Dev Biol 20, 781-810.
- Hovanes, K. et al. (2000) Nucleic Acids Res 28, 1994-2003.
- Hovanes, K. et al. (2001) Nat Genet 28, 53-7.
- Kobielak, A. et al. (2001) Acta Biochim Pol 48, 221-6.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7727 Biotinylated Protein Ladder Detection Pack
- 3224 Dvl2 (30D2) Rabbit mAb
- 3216 Dvl2 Antibody
- 3218 Dvl3 Antibody
- 2568 Phospho-LRP6 (Ser1490) Antibody
- 6883 SignalFire™ ECL Reagent
- 12757 SignalFire™ Elite ECL Reagent
- 12630 SignalFire™ Plus ECL Reagent
- 2391 Wnt3a Antibody
- 2392 Wnt5a Antibody
- 9562 β-Catenin Antibody
- 9581 β-Catenin Antibody (Amino-terminal Antigen)
- 9587 β-Catenin Antibody (Carboxy-terminal Antigen)
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.